Obesity Alters Endoxifen Plasma Levels in Young Breast Cancer Patients: A Pharmacometric Simulation Approach. Issue 3 (23rd July 2020)
- Record Type:
- Journal Article
- Title:
- Obesity Alters Endoxifen Plasma Levels in Young Breast Cancer Patients: A Pharmacometric Simulation Approach. Issue 3 (23rd July 2020)
- Main Title:
- Obesity Alters Endoxifen Plasma Levels in Young Breast Cancer Patients: A Pharmacometric Simulation Approach
- Authors:
- Mueller‐Schoell, Anna
Klopp‐Schulze, Lena
Schroth, Werner
Mürdter, Thomas
Michelet, Robin
Brauch, Hiltrud
Huisinga, Wilhelm
Joerger, Markus
Neven, Patrick
Koolen, Stijn L.W.
Mathijssen, Ron H.J.
Copson, Ellen
Eccles, Diana
Chen, Sylvia
Chowbay, Balram
Tfayli, Arafat
Zgheib, Nathalie K.
Schwab, Matthias
Kloft, Charlotte - Abstract:
- Abstract : Endoxifen is one of the most important metabolites of the prodrug tamoxifen. High interindividual variability in endoxifen steady‐state concentrations (CSS, min ENDX ) is observed under tamoxifen standard dosing and patients with breast cancer who do not reach endoxifen concentrations above a proposed therapeutic threshold of 5.97 ng/mL may be at a 26% higher recurrence risk compared with patients with endoxifen concentrations exceeding this value. In this investigation, 10 clinical tamoxifen studies were pooled (1, 388 patients) to investigate influential factors on CSS, min ENDX using nonlinear mixed‐effects modeling. Age and body weight were found to significantly impact CSS, min ENDX in addition to CYP2D6 phenotype. Compared with postmenopausal patients, premenopausal patients had a 30% higher risk for subtarget CSS, min ENDX at tamoxifen 20 mg per day. In treatment simulations for distinct patient subpopulations, young overweight patients had a 3.1–13.8‐fold higher risk for subtarget CSS, min ENDX compared with elderly low‐weight patients. Considering ever‐rising obesity rates and the clinical importance of tamoxifen for premenopausal patients, this subpopulation may benefit most from individualized tamoxifen dosing.
- Is Part Of:
- Clinical pharmacology & therapeutics. Volume 108:Issue 3(2020)
- Journal:
- Clinical pharmacology & therapeutics
- Issue:
- Volume 108:Issue 3(2020)
- Issue Display:
- Volume 108, Issue 3 (2020)
- Year:
- 2020
- Volume:
- 108
- Issue:
- 3
- Issue Sort Value:
- 2020-0108-0003-0000
- Page Start:
- 661
- Page End:
- 670
- Publication Date:
- 2020-07-23
- Subjects:
- Pharmacology -- Periodicals
Therapeutics -- Periodicals
615.5 - Journal URLs:
- http://www.nature.com/clpt/index.html ↗
http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1532-6535 ↗
http://www.nature.com/ ↗
http://firstsearch.oclc.org ↗
http://www.mosby.com/cpt ↗
http://www.sciencedirect.com/science/journal/00099236 ↗
http://www2.us.elsevierhealth.com/scripts/om.dll/serve?action=searchDB&searchdbfor=home&id=cp ↗ - DOI:
- 10.1002/cpt.1960 ↗
- Languages:
- English
- ISSNs:
- 0009-9236
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3286.330000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 19207.xml